Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagonist Therapeutics Inc (NQ: PTGX ) 41.68 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Protagonist Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 Next > Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis December 13, 2023 Via ACCESSWIRE Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals December 12, 2023 Via ACCESSWIRE Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib November 27, 2023 Via ACCESSWIRE Protagonist Therapeutics Reports Granting of Inducement Awards November 16, 2023 Via ACCESSWIRE Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On November 16, 2023 Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. Via The Motley Fool The Latest Analyst Ratings for Protagonist Therapeutics November 03, 2023 Via Benzinga Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 02, 2023 Via ACCESSWIRE Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications October 09, 2023 Via ACCESSWIRE Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) November 09, 2023 Via ACCESSWIRE Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting November 02, 2023 Via ACCESSWIRE Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis November 01, 2023 Via ACCESSWIRE Protagonist Therapeutics to Participate in Upcoming Investor Conferences November 01, 2023 Via ACCESSWIRE Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors October 30, 2023 Via ACCESSWIRE What 6 Analyst Ratings Have To Say About Protagonist Therapeutics September 25, 2023 Via Benzinga Protagonist Receives $34 Million from Warrant Exercises August 09, 2023 Via ACCESSWIRE Expert Ratings for Protagonist Therapeutics July 06, 2023 Via Benzinga Protagonist Therapeutics Reports Granting of Inducement Award October 03, 2023 Via ACCESSWIRE Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty September 22, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... Via FinancialNewsMedia Protagonist Therapeutics to Present at Upcoming Investor Conferences September 05, 2023 Via ACCESSWIRE Protagonist Therapeutics Reports Granting of Inducement Award August 16, 2023 Via ACCESSWIRE Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 03, 2023 Via ACCESSWIRE Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter July 27, 2023 The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Via Benzinga Protagonist Therapeutics Reports Granting of Inducement Award July 18, 2023 Via ACCESSWIRE Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday July 13, 2023 We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning. Via InvestorPlace Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive July 06, 2023 JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35, Via Benzinga Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday July 06, 2023 Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at... Via Benzinga Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment July 05, 2023 Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session July 04, 2023 Via Benzinga Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis July 04, 2023 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's Intraday Session July 03, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.